Postmenop is a form of estrogen, a female sex hormone that regulates many processes in the body.
Some Postmenop products placed directly into the vagina are used for "local" treatment of vaginal menopause symptoms (such as dryness, burning, and irritation). Other vaginal Postmenop products are used for treating vaginal menopause symptoms and symptoms that affect other parts of the body (such as hot flashes). This type of vaginal Postmenop has "systemic" effects, meaning that it can affect parts of the body other than where the medicine is directly applied.
This medication guide provides information about Postmenop for local treatment of vaginal symptoms of menopause (such as dryness, itching, irritation, and pain during sexual intercourse).
Postmenop (local) may also be used for purposes not listed in this medication guide.
Postmenop indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored
Postmenop is a Hormone Replacement Therapy (HRT). It contains the female hormone Postmenop.
Postmenop is used in postmenopausal women, particularly in women who have had their womb removed (have had a hysterectomy) and therefore do not require combined oestrogen/progestagen therapy.
Postmenop is
Used for: Relief of symptoms occurring after menopause: During the menopause, the amount of oestrogen produced by a woman’s body drops. This can cause symptoms such as hot face, neck and chest (‘hot flushes’). Postmenop alleviates these symptoms after menopause. Postmenop should only be prescribed if the symptoms seriously hinder the patient’s daily life.
Prevention of osteoporosis (thinning of the bones), if the patient is at high risk of future fracture and if unable to take other medications for this purpose.
There is only limited experience of treating women older than 65 years.
How should I use Postmenop?
Use Postmenop spray as directed by your doctor. Check the label on the medicine for exact dosing instructions.
An extra patient leaflet is available with Postmenop spray. Talk to your pharmacist if you have questions about this information.
Postmenop spray is applied to the inside of the forearm, between the elbow and the wrist. Do not apply Postmenop spray to any other area of the body besides the forearm. If you get Postmenop spray on another area of your skin, wash that area of your skin with soap and water right away.
Apply Postmenop spray to clean, intact skin only. Be sure the area is completely dry before applying Postmenop spray.
Do not apply Postmenop spray to skin that is irritated or broken. Do not apply it to your face, in or around the vagina, or to your breasts.
You will need to prime the pump before using it for the first time. To prime the pump, leave the cover on, hold the bottle in an upright position, and press the pump completely down 3 times. The pump is now ready for use.
Hold the applicator upright and rest the plastic cone flat against the skin of your forearm. Be sure there are no gaps between the cone and your skin. Press the pump firmly and fully 1 time. Do NOT massage or rub the medicine in.
If you are applying more than 1 spray, move the cone to an area of the skin next to but not touching the previous area. Then press the pump firmly and fully again.
Replace the protective cover over the pump after use.
Wash your hands with soap and water after using Postmenop spray.
Allow the medicine to dry for at least 2 minutes before dressing.
Do not wash the application area for at least 1 hour after you apply Postmenop spray.
Do not allow others to apply Postmenop spray for you. Do not allow other people or pets to come into contact with the site where you applied Postmenop spray. If someone else comes into contact with Postmenop spray, have them wash the area with soap and water right away.
This pump contains enough medicine for 75 sprays (not counting the 3 sprays used to prime the pump). Throw away the pump after 75 sprays have been used, even if there is still medicine left in the pump. It may no longer give the correct amount of medicine with each dose.
Use Postmenop spray at the same time each day.
If you miss a dose of Postmenop spray, use it as soon as possible. If your next dose is less than 12 hours away, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Postmenop spray.
Uses of Postmenop in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored
This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure) and by men to treat prostate cancer.
How to use Postmenop intramuscular
Read the Patient Information Leaflet if available from your pharmacist before you start using this medication and each time you get a refill. If you have any questions, ask your doctor or pharmacist.
This medication is injected into a muscle as directed by your doctor, usually every 4 weeks. For the treatment of prostate cancer, this medication is usually given every 1 to 2 weeks. The dosage is based on your medical condition and response to treatment.
If you are using this medication at home, learn all preparation and usage instructions from your health care professional. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. If stored at low temperatures, crystal may form in the liquid. To dissolve these crystals, simply warm the product to room temperature prior to use. Learn how to store and discard medical supplies safely.
Use this medication regularly to get the most benefit from it. To help you remember, mark your calendar with a reminder of when to receive your doses.
Tell your doctor if your condition does not improve or if it worsens.
Postmenop description
sponsored
Generally refers to the 17-beta-isomer of Postmenop, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Postmenop-17-beta is the most potent form of mammalian estrogenic steroids. In humans, it is produced primarily by the cyclic ovaries and the placenta. It is also produced by the adipose tissue of men and postmenopausal women. The 17-alpha-isomer of Postmenop binds weakly to estrogen receptors (receptors, estrogen) and exhibits little estrogenic activity in estrogen-responsive tissues. Various isomers can be synthesized.
Postmenop dosage
Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. A woman without a uterus does not need a progestin. In some cases, however, hysterectomized women with a history of endometriosis may need a progestin.
Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.
Treatment Of Moderate To Severe Vasomotor Symptoms Due To Menopause
Start therapy with 0.025 mg per day applied to the skin once weekly. Therapy should be started at the lowest effective dose and the shortest duration consistent with the treatment goals. Attempts to taper or discontinue the medication should be made at 3 to 6 month intervals.
Treatment Of Moderate To Severe Symptoms Of Vulvar And Vaginal Atrophy Due To Menopause
Start therapy with 0.025 mg per day applied to the skin once weekly. Therapy should be started at the lowest effective dose and the shortest duration consistent with the treatment goals. Attempts to taper or discontinue the medication should be made at 3 to 6 month intervals.
Treatment Of Hypoestrogenism Due To Hypogonadism, Castration, Or Primary Ovarian Failure
Start therapy with 0.025 mg per day applied to the skin once weekly. The dose should be adjusted as necessary to control symptoms. Clinical responses (relief of symptoms) at the lowest effective dose should be the guide for establishing administration of the Postmenop transdermal system, especially in women with an intact uterus.
Prevention Of Postmenopausal Osteoporosis
Start therapy with 0.025 mg per day applied to the skin once weekly.
Application Of The Postmenop Transdermal System
Site Selection
The adhesive side of Postmenop should be placed on a clean, dry area of the lower abdomen or the upper quadrant of the buttock.
Postmenop should not be applied to or near the breasts.
The sites of application must be rotated, with an interval of at least 1-week allowed between applications to the same site.
The area selected should not be oily, damaged, or irritated. The waistline should be avoided, since tight clothing may rub the transdermal system off.
Application to areas where sitting would dislodge Postmenop should also be avoided.
Application
Postmenop should be applied immediately after opening the pouch and removing the protective liner.
Postmenop should be pressed firmly in place with the fingers for at least 10 seconds, making sure there is good contact, especially around the edges.
If the system lifts, apply pressure to maintain adhesion.
In the event that a system should fall off reapply it to a different location. If the system cannot be reapplied, a new system should be applied for the remainder of the 7-day dosing interval.
Only one system should be worn at any one time during the 7-day dosing interval.
Swimming, bathing, or using a sauna while using Postmenop has not been studied, and these activities may decrease the adhesion of the system and the delivery of Postmenop.
Removal Of The Postmenop Transdermal System
Removal of Postmenop should be done carefully and slowly to avoid irritation of the skin.
Should any adhesive remain on the skin after removal of the Postmenop system, allow the area to dry for 15 minutes. Then gently rubbing the area with an oil-based cream or lotion should remove the adhesive residue.
Used patches still contain some active hormones. Each patch should be carefully folded in half so that it sticks to itself before throwing it away.
How supplied
Dosage Forms And Strengths
Postmenop (Postmenop transdermal system), 0.025 mg per day—each 6.5 cm² system contains 2 mg of Postmenop
Postmenop (Postmenop transdermal system), 0.0375 mg per day—each 9.375 cm² system contains 2.85 mg of Postmenop
Postmenop (Postmenop transdermal system), 0.05 mg per day—each 12.5 cm² system contains 3.8 mg of Postmenop
Postmenop (Postmenop transdermal system), 0.060 mg per day—each 15 cm² system contains 4.55 mg of Postmenop
Postmenop (Postmenop transdermal system), 0.075 mg per day—each 18.75 cm² system contains 5.7 mg of Postmenop
Postmenop (Postmenop transdermal system), 0.1 mg per day—each 25.0 cm² system contains 7.6 mg of Postmenop
Postmenop (Postmenop transdermal system), 0.025 mg per day — each 6.5 cm² system contains 2 mg of Postmenop USP Individual Carton of 4 systems NDC 50419-454-04
Postmenop (Postmenop transdermal system), 0.0375 mg per day — each 9.375 cm² system contains 2.85 mg of Postmenop USP Individual Carton of 4 systems NDC 50419-456-04
Postmenop (Postmenop transdermal system), 0.05 mg per day — each 12.5 cm² system contains 3.8 mg of Postmenop USP Individual Carton of 4 systems NDC 50419-451-04
Postmenop (Postmenop transdermal system), 0.06 mg per day — each 15 cm² system contains 4.55 mg of Postmenop USP Individual Carton of 4 systems NDC 50419-459-04
Postmenop (Postmenop transdermal system), 0.075 mg per day — each 18.75 cm² system contains 5.7 mg of Postmenop USP Individual Carton of 4 systems NDC 50419-453-04
Postmenop (Postmenop transdermal system), 0.1 mg per day — each 25 cm² system contains 7.6 mg of Postmenop USP Individual Carton of 4 systems NDC 50419-452-04
Storage And Handling
Store at 20°C to 25°C (66°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Do not store above 86°F (30°C).
Do not store unpouched. Apply immediately upon removal from the protective pouch.
Used transdermal systems still contain active hormone. To discard, fold the sticky side of the transdermal system together, place it in a sturdy child-proof container, and place this container in the trash. Used transdermal systems should not be flushed in the toilet.
Manufactured for: Bayer HealthCare Pharmaceuticals Inc. Whippany, NJ 07981. Manufactured by 3M Drug Delivery Systems, Northridge, CA 91324. Revised: Oct 2013
Postmenop is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of lovastatin
Pharmacokinetics Itraconazol Ketoconazol Erythromyci Clarithromyci Telithromyci HIV protease inhibitor Nefazodon Cyclosporin Large quantities of grapefruit juice (>1 quart daily
Interactions with lipid-lowering drugs that can cause myopathy when given alone
The risk of myopathy is also increased by the following lipid-lowering drugs that are not potent CYP3A4 inhibitors, but which can cause myopathy when given alone
See WARNINGS, Myopathy/Rhabdomyolysis Gemfibrozi Other fibrate Niacin (nicotinic acid) (=1 g/day
Other drug interaction
Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin
Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class
Coumarin Anticoagulants: In a small clinical trial in which lovastatin was administered to warfarin treated patients, no effect on prothrombin time was detected. However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin. Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin. It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of lovastatin is changed, the same procedure should be repeated. Postmenop therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants
Propranolol: In normal volunteers, there was no clinically significant pharmacokinetic o pharmacodynamic interaction with concomitant administration of single doses of lovastatin and propranolol
Digoxin: In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations
Oral Hypoglycemic Agents: In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide
See WARNINGS and Boxed Warning regarding the potential adverse effects on the fetus, the induction of malignant neoplasms, gallbladder disease, cardiovascular disease, elevated blood pressure, and hypercalcemia.
Skin irritation: In controlled clinical studies with Postmenop (Postmenop transdermal), the most commonly reported adverse events were topical reactions of erythema and/or pruritus at the application site. In general these reactions caused patients little or no discomfort, and led to premature discontinuation of treatment in 0.9% (3/317) of patients in these trials. The rate of application site reactions, based on 8,135 applications of the 0.025, 0.05, and 0.1 Postmenop (Postmenop transdermal) systems in these trials was 6.1 per 100 applications (4.9, 5.4, 10.7 for the 3 Postmenop (Postmenop transdermal) doses respectively) compared to 6.2 in the placebo treated patients (2,014 applications).
In a placebo-controlled trial of Postmenop (Postmenop transdermal) 0.025, 0.05, and 0.1 conducted in 196 patients in the US, the adverse events reported by at least 5% of patients in 1 or more of the treatment groups are shown in Table 5.
Table 5: Incidence of Adverse Events >5% in a Placebo-Controlled Study of Postmenop Data Are Expressed as % of Treatment Group
Placebo
Postmenop
Postmenop
Postmenop
Adverse Event
0.025 mg/day
0.05 mg/day
0.1 mg/day
(N=54)
(N=48)
(N=47)
(N=47)
Breast Pain
3.7
25.0
44.7
46.8
Headache
22.2
18.8
8.5
6.4
Infection
7.4
10.4
10.6
8.5
Injury Accident
3.7
10.4
4.3
2.1
Anxiety
0
8.3
2.1
0
Emotional Lability
1.9
8.3
2.1
6.4
Arthralgia
1.9
6.3
2.1
4.3
Flu Syndrome
7.4
6.3
6.4
8.5
Joint Disorder
0
6.3
0
0
Pruritus
1.9
6.3
12.8
0
Rhinitis
1.9
6.3
4.3
4.3
Abdominal Pain
9.3
4.2
10.6
2.1
General Edema
1.9
4.2
6.4
6.4
Monilia Vagina
5.6
4.2
8.5
4.3
Nausea
1.9
4.2
10.6
8.5
Peripheral Edema
0
4.2
2.1
6.4
Sinusitis
7.4
4.2
2.1
4.3
Asthenia
1.9
2.1
10.6
6.4
Back Pain
3.7
2.1
2.1
6.4
Diarrhea
1.9
2.1
8.5
0
Dysmenorrhea
0
2.1
2.1
6.4
Enlarged Abdomen
0
2.1
2.1
6.4
Enlarged Breast
0
2.1
2.1
8.5
Rash
5.6
2.1
4.3
2.1
Anemia
0
0
6.4
4.3
Gastroenteritis
1.9
0
0
6.4
Hyperlipemia
5.6
0
0
2.1
Leukorrhea
0
0
12.8
0
Paresthesia
1.9
0
6.4
0
Urogenital Adverse Events : In the US placebo-controlled study, 72 patients were included who had intact uteri. As expected, after 12-13 weeks of continuous unopposed therapy, findings of endometrial hyperplasia (diagnosed either by endometrial biopsy and/or ultrasonography) were increased with increasing doses of Postmenop (placebo: 0/18 patients; Postmenop (Postmenop transdermal) 0.025: 1/14 (7.1%); Postmenop (Postmenop transdermal) 0.05: 12/22 (54.5%); Postmenop (Postmenop transdermal) 0.1: 10/18 (55.6%). In the 86 patients who had not previously undergone a total hysterectomy, vaginal bleeding was also increased with increasing doses of Postmenop [placebo: 2/21 patients (9.5%); Postmenop (Postmenop transdermal) 0.025: 6/19 (31.6%); Postmenop (Postmenop transdermal) 0.05: 14/25 (56.0%); Postmenop (Postmenop transdermal) 0.1: 12/21 (57.1%)].
In 2 long-term studies involving a total of 488 patients treated for a mean duration of 618 days and up to 3.5 years, the nature and incidence of adverse events did not change with prolonged duration of treatment.
The following additional adverse reactions have been reported with estrogen therapy:
1. Genitourinary System. Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow; breakthrough bleeding, spotting; increase in size of uterine leiomyomata; vaginal candidiasis; change in amount of cervical secretion.
4. Skin. Chloasma or melasma that may persist when drug is discontinued; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair; hirsutism.
5. Eyes. Steepening of corneal curvature: intolerance to contact lenses.
6. Central Nervous System. Headache, migraine, dizziness; mental depression; chorea.
7. Miscellaneous. Increase or decrease in weight; reduced carbohydrate tolerance; aggravation of porphyria; edema; changes in libido.
Postmenop can harm an unborn baby or cause birth defects. Do not use if you are pregnant.
You should not use this medication if you have any of the following conditions: liver disease, a bleeding disorder, unusual vaginal bleeding, a history of breast or uterine cancer, or if you have ever had a heart attack, stroke, or a blood clot.
Postmenop may increase your risk of developing a condition that may lead to uterine cancer. Your doctor may prescribe a progestin while you are using Postmenop, to help lower this risk. Report any unusual vaginal bleeding right away.
Long-term use of Postmenop may increase your risk of breast cancer, heart attack, stroke, or blood clot. Talk with your doctor about your individual risks before using Postmenop transdermal long term.
Have regular physical exams and self-examine your breasts for lumps on a monthly basis while using Postmenop transdermal.
Postmenop transdermal should not be used to prevent heart disease, stroke, or dementia, because this medicine may actually increase your risk of developing these conditions.
Progynova (Antigua & Barbuda, Argentina, Aruba, Australia, Austria, Bahamas, Barbados, Belgium, Bermuda, Cayman Islands, Chile, China, Colombia, Costa Rica, Dominican Republic, El Salvador, Ethiopia, Finland, France, Grenada, Guatemala, Guyana, Honduras, Hong Kong, India, Indonesia, Israel, Italy, Jamaica, Lithuania, Luxembourg, Malaysia, Malta, Netherlands, New Zealand, Nicaragua, Norway, Panama, Peru, Philippines, Russian Federation, Saint Lucia, Singapore, South Africa, South Korea, Spain, Suriname, Switzerland, Taiwan, Thailand, Trinidad & Tobago, United Kingdom, Vietnam)
DailyMed. "ESTRADIOL HEMIHYDRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Postmenop are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Postmenop. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
Consumer reported age
No survey data has been collected yet
Consumer reviews
There are no reviews yet. Be the first to write one!